**[Exclusive]** The Lancet Robotics completes tens of millions of yuan in Pre-A round financing, continuously promoting clinical research of joint replacement surgical robots.

Recently, Shenzhen Scalpel Robot Co., Ltd. (hereinafter referred to as: Scalpel Robot) announced the completion of tens of millions of yuan in Pre-A round financing, with Haibang Fenghua as the investor. It is understood that this round of financing will be mainly used to promote the clinical research of the company's hip replacement surgical robot and knee replacement surgical robot, as well as the market promotion of the digital orthopedic intelligent software that is about to obtain a registration certificate.

Recently, Shenzhen Scalpel Robot Co., Ltd. (hereinafter referred to as: Scalpel Robot) announced the completion of tens of millions of yuan in Pre-A round financing, with Haibang Fenghua as the investor.

It is understood that this round of financing will be mainly used to promote the clinical research of the company's hip replacement surgical robot and knee replacement surgical robot, as well as the market promotion of the digital orthopedic intelligent software that is about to obtain a registration certificate. At present, the company's independently developed hip replacement surgical robot has completed multiple clinical studies and achieved good clinical application effects, and the knee replacement surgical robot product has obtained a type inspection report and is about to enter the clinical research stage.

Previously, the company completed tens of millions of yuan in angel round financing from Yuansheng Venture Capital and Shenzhen Qianhai Mother Fund in October 2020.

Since its establishment in July 2018, Scalpel Robot has always focused on the innovation of intelligent orthopedic surgical solutions, and is committed to achieving intelligent, minimally invasive, and precise orthopedic surgery. The core founding team members all come from well-known universities such as Tsinghua University, Harbin Institute of Technology, Shanghai Jiao Tong University, and National Taiwan University, and have rich experience in the research and development of surgical robots. In three years, Scalpel Robot has completed dozens of intellectual property layouts, obtained the recognition of many well-known domestic orthopedic experts, and established long-term cooperative relationships with many well-known orthopedic manufacturers.

Aging population and precision medicine give rise to

 Development of orthopedic surgical robots

According to the latest census data, the population of China aged 60 and above has reached 264.02 million, accounting for 18.70% of the total population. The degree of population aging is further deepening, which leads to a year-on-year increase in the incidence of diseases related to joint and sports medicine injuries. Data shows that the total number of joint replacement surgeries in China in 2020 exceeded 900,000, including 580,000 hip joints and 330,000 knee joints, maintaining high-speed growth for many consecutive years. However, compared with the volume of joint replacement surgeries in developed markets in Europe and America, there is still untapped potential in the Chinese market.

In addition, in recent years, the clinical demand for precision medicine has been continuously growing. Traditional orthopedic surgeries mostly rely on the experience of the chief surgeon and a clear view of the lesion. Large incisions and high radiation doses may increase the risk of surgery. However, robot-assisted orthopedic surgery can accurately reach the lesion, make small incisions, have high stability, and achieve good postoperative effects. Therefore, surgical robots are gradually being recognized clinically.

At present, orthopedic surgical robots in China are still in the initial stage of development, and no domestic orthopedic joint replacement surgical robots have been registered and approved in China. Foreign Brand joint replacement surgical robots on the market only meet a small part of the market demand due to their high prices and usage costs. High-performance domestic brands are expected to achieve overtaking on a curve.

Intelligent and precise, solving the pain points of traditional surgery

In response to the pain points of traditional orthopedic surgery, such as high operational requirements and large incisions, Scalpel Robot has integrated a number of independent innovation technologies and functions. Through the integration of digital and intelligent tools and surgical robots, it has created a joint replacement surgical robot that can provide functions such as preoperative planning, intraoperative real-time positioning and navigation, and postoperative simulation evaluation. It can provide doctors with a minimally invasive surgical solution with high precision, low radiation, and high safety, while reducing patient pain, shortening recovery time, and improving quality of life.

At present, the company's first product, the hip replacement surgical robot, has been successfully used in robot-assisted hip replacement surgeries in many well-known tertiary hospitals, including the Affiliated Drum Tower Hospital of Nanjing Medical University.

In addition, the company has other products, including knee replacement surgical robots, which are undergoing pre-clinical animal experiments and specimen experiments and are about to start clinical research.

With a large population base and an intensifying aging population, China has become the second largest joint replacement surgery market after the United States. It is believed that in the near future, the use of Scalpel joint replacement surgical robots can change the monopoly of imported products, meet a wider range of clinical needs, and help the development of domestic high-end medical devices.

Scalpel hip replacement surgical robot

As the investor in this financing, Li Yang, investment director of Haibang Fenghua, said: "The application of joint replacement surgical robots conforms to the general trend of digital and intelligent development in orthopedics. The Scalpel Robot team has a strong engineer culture and well balances the maturity, completeness of the product, and the speed of R&D progress. It is expected to surpass its competitors with strong execution capabilities. Relying on excellent products and abundant clinical resources, Scalpel Robot is expected to become a leading digital platform enterprise in the future orthopedic field of diagnosis, AI planning, surgical robots, and consumables, with its outstanding technical strength and differentiated market strategy. Haibang Venture Capital remains optimistic about the company's expansion capabilities in the field of digital orthopedics and looks forward to the company achieving new achievements in further product layout and internationalization."

As the clinical trial party, Professor Jiang Qing, chief physician of the Affiliated Drum Tower Hospital of Nanjing Medical University, said: "Surgical robots are a new type of medical device that integrates clinical medicine, biomechanics, mechanics, computer science, optics, and many other disciplines. Surgical robots, through precise preoperative planning and flexible robotic arms, assist doctors in performing complex and precise surgical operations in a minimally invasive manner. The total number of total hip arthroplasty surgeries in China each year is less than one-third of that in the United States, which cannot meet the urgent needs of a large number of patients, especially elderly patients, for a high-quality life. Hip replacement surgical robots assist doctors in developing personalized surgical plans for patients, achieving visualization of the surgical process and precise prosthesis implantation, thereby helping more doctors benefit a wider range of patients. In the past, this field has been monopolized by foreign hip joint surgical robots, with high market prices. The research and development of surgical robots with independent intellectual property rights, safety, reliability, and affordable prices in China is of great practical significance for breaking foreign monopolies, serving a large number of patients, and promoting the development of China's high-end medical equipment industry."

This information comes from the Internet. Please contact us to delete it if there is any infringement.